Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794455 · ClinicalTrials.gov registry record · Phase 4
Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression
A Phase 4 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT01794455 is a Phase 4 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 1 participants.
The verdict
NCT01794455, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This pilot proposal will test the hypothesis that altered cerebral vessel reactivity and cerebral hypoperfusion (decreased blood flow to the brain) is a core mechanism underlying the relationship between vascular disease and depression in older adults. The long-term objective of this line of research is to: A) determine the relationship between vascular reactivity, cerebral hypoperfusion and the persistence of late-life depression and B) determine if improving cerebral perfusion with angiotensin receptor blockers (ARBs) improves depression outcomes.
Interventions
- DRUG Sertraline
- DRUG Candesartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01794455
The ClinicalTrials.gov registry entry for NCT01794455 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sertraline is the first listed.
NCT01794455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01794455 about?
NCT01794455 is a clinical study titled "Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression". This pilot proposal will test the hypothesis that altered cerebral vessel reactivity and cerebral hypoperfusion (decreased blood flow to the brain) is a core mechanism underlying the relationship between vascular disease and depression in older adults. The long-term objective of this line of researc...
What is the current status of trial NCT01794455?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2013-05. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01794455?
The interventions under investigation include: Sertraline (DRUG), Candesartan (DRUG).
Who is sponsoring clinical trial NCT01794455?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.